E-ISSN 2231-3206 | ISSN 2320-4672
 
2024, Vol: 14, Issue: 4
14 / 4Current Issue Online FirstArchiveAims and ScopeAbstracting & IndexingMost Accessed ArticlesMost Downloaded ArticlesMost Cited Articles
Required files to be uploaded

Authorship Declaration

Original Research

Online Publishing Date:
30 / 08 / 2021

 


Ocular side effects in tuberculosis patients receiving direct observed therapy containing ethambutol

Aarti Dave, Surohi Shah, Yogin Mistry, Naina Chaturvedi, Disha Jariwala.


Abstract
Background: India is among the largest countries to implement the revised national tuberculosis (TB) control program (RNTCP). Ocular toxicity of ethambutol has been known since 1962. It can be halted with early detection and cessation of the contributing drug.

Aims and Objectives: This study aims to detect early ocular toxicity of ethambutol in TB patients under directly observed treatment strategy (DOTS).

Materials and Methods: This was a prospective cross-sectional study of 30 patients getting AKT including ethambutol along with isoniazid, rifampicin, and pyrazinamide under RNTCP‑DOTS center at a tertiary care hospital. The detailed history, best-corrected visual acuity (BCVA), color vision, fundus examination, visual field, retinal nerve fiber layer (RNFL) thickness, and central subfield macular thickness were carried out in all patients pretreatment and then at the 2nd month of treatment.

Results: The mean age of patient was 44.87 years. Reduced visual acuity from the baseline was noted at the second in 23.33% of the right eyes (P = 0.01) and 30% of the left eyes (P < 0.01). Mean temporal RNFL thickness was significantly reduced from baseline after 2 months of treatment (P = 0.046). No significant difference was observed with color vision and visual fields pre- and post-treatment.

Conclusion: The assessment of BCVA, color vision, visual field, RNFL, and macular thickness is essential at baseline and thereafter at frequent intervals to detect early ethambutol toxicity and probable reversible visual loss.

Key words: Ethambutol; Retinal Nerve Fiber Layer; Color Vision; Visual Field


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Aarti Dave
Articles by Surohi Shah
Articles by Yogin Mistry
Articles by Naina Chaturvedi
Articles by Disha Jariwala
on Google
on Google Scholar


How to Cite this Article
Pubmed Style

Dave A, Shah S, Mistry Y, Chaturvedi N, Jariwala D. Ocular side effects in tuberculosis patients receiving direct observed therapy containing ethambutol. Natl J Physiol Pharm Pharmacol. 2022; 12(2): 127-131. doi:10.5455/njppp.2022.12.08272202113082021

Web Style

Dave A, Shah S, Mistry Y, Chaturvedi N, Jariwala D. Ocular side effects in tuberculosis patients receiving direct observed therapy containing ethambutol. https://www.njppp.com/?mno=105661 [Access: March 15, 2024]. doi:10.5455/njppp.2022.12.08272202113082021

AMA (American Medical Association) Style

Dave A, Shah S, Mistry Y, Chaturvedi N, Jariwala D. Ocular side effects in tuberculosis patients receiving direct observed therapy containing ethambutol. Natl J Physiol Pharm Pharmacol. 2022; 12(2): 127-131. doi:10.5455/njppp.2022.12.08272202113082021


Vancouver/ICMJE Style

Dave A, Shah S, Mistry Y, Chaturvedi N, Jariwala D. Ocular side effects in tuberculosis patients receiving direct observed therapy containing ethambutol. Natl J Physiol Pharm Pharmacol. (2022), [cited March 15, 2024]; 12(2): 127-131. doi:10.5455/njppp.2022.12.08272202113082021


Harvard Style

Dave, A., Shah, . S., Mistry, . Y., Chaturvedi, . N. & Jariwala, . D. (2022) Ocular side effects in tuberculosis patients receiving direct observed therapy containing ethambutol. Natl J Physiol Pharm Pharmacol, 12 (2), 127-131. doi:10.5455/njppp.2022.12.08272202113082021


Turabian Style

Dave, Aarti, Surohi Shah, Yogin Mistry, Naina Chaturvedi, and Disha Jariwala. 2022. Ocular side effects in tuberculosis patients receiving direct observed therapy containing ethambutol. National Journal of Physiology, Pharmacy and Pharmacology, 12 (2), 127-131. doi:10.5455/njppp.2022.12.08272202113082021


Chicago Style

Dave, Aarti, Surohi Shah, Yogin Mistry, Naina Chaturvedi, and Disha Jariwala. "Ocular side effects in tuberculosis patients receiving direct observed therapy containing ethambutol." National Journal of Physiology, Pharmacy and Pharmacology 12 (2022), 127-131. doi:10.5455/njppp.2022.12.08272202113082021


MLA (The Modern Language Association) Style

Dave, Aarti, Surohi Shah, Yogin Mistry, Naina Chaturvedi, and Disha Jariwala. "Ocular side effects in tuberculosis patients receiving direct observed therapy containing ethambutol." National Journal of Physiology, Pharmacy and Pharmacology 12.2 (2022), 127-131. Print. doi:10.5455/njppp.2022.12.08272202113082021


APA (American Psychological Association) Style

Dave, A., Shah, . S., Mistry, . Y., Chaturvedi, . N. & Jariwala, . D. (2022) Ocular side effects in tuberculosis patients receiving direct observed therapy containing ethambutol. National Journal of Physiology, Pharmacy and Pharmacology, 12 (2), 127-131. doi:10.5455/njppp.2022.12.08272202113082021


Author LoginReviewer LoginAbout PublisherEditorial PoliciesEditorial Review PolicyPeer Review PolicyEditorial & Peer Review ProcessPublication Ethics and Publication Malpractice StatementConflict of Interest PolicyPlagiarism PolicyProtection of Research Participants (Statement On Human And Animal Rights)Corrections, Retractions & Expressions of ConcernSelf-Archiving PoliciesStatement of Informed ConsentAdvertising PolicyTerms of UseLicense InformationCopyright Information

About National Journal of Physiology, Pharmacy and Pharmacology

  National Journal of Physiology, Pharmacy and Pharmacology is a monthly peer reviewed journal.  The journal is having open access polic ... Read more.



For best results, please use Internet Explorer or Google Chrome.

Contact Information


Publisher

publishernjppp@gmail.com

 

Editorial query

editornjppp1@gmail.com

MOB - 8780040272